ArticleiLIVER2022
Identification of publication characteristics and research trends in the management of gallbladder cancer.
Article in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To date, no comprehensive analysis of gallbladder cancer (GBC) management has been reported. We aimed to identify the publication characteristics and research trends in managing GBC over the past three decades. Methods: We selected the 100 most cited articles and performed a bibliometric analysis to summarize the publication characteristics, explore research hotspots, and identify research trends in the management of GBC. Results: The total citations of the included articles ranged from 123 to 1822. Period II (2001-2010) yielded the highest number of included articles, whereas the lowest was in Period III (2011-2020). The United States and Japan published the most papers, in which the Memorial Sloan-Kettering Cancer Center and Nagoya University were the leading institutions, respectively. The most influential authors were Blumgart LH and Fong YM from the United States. Cooperation among countries, institutions, and authors was weak. The Conclusions: Surgery remains the preferred treatment, while there is a tendency toward adjuvant and systemic therapy in GBC management. An increase in local and international collaboration for managing GBC is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.